RxDoctor Payments DataLook up a doctor →

Iloabueke Chineke, MD

Hematology & Oncology · Casper, WYNPI 1740700798

Payments from drug & device makers

$10,571in general payments, 2019–2025

Across 295 payments — averaging $35.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Daiichi Sankyo Inc.$843
  • Pfizer$686
  • Merck$374
  • Novartis$343
  • E.r. Squibb & Sons, L.L.C.$332
  • plus $5K from 51 others

What the payments were for

  • Consulting fees$3,40032%
  • Food & beverage$6,59962%
  • Education$5725%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hematology & oncology providers in Wyomingto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$8,375,308
Medicare patients
622
Services billed
276,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VenclextaVenetoclax54$452,136
StivargaRegorafenib13$299,556
LenvimaLenvatinib Mesylate12$282,554
IbrancePalbociclib16$258,778
CalquenceAcalabrutinib Maleate17$254,157
Lenalidomide15$235,912
BrukinsaZanubrutinib12$181,705
Abiraterone Acetate33$93,366
Imatinib Mesylate12$24,949
EliquisApixaban23$13,604
Anastrozole117$2,020
Exemestane24$1,994
Potassium Chloride57$1,680
Ondansetron OdtOndansetron51$1,580
Acyclovir73$1,073

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVenclexta$304$452,13654 claims
BayerStivarga$79$299,55613 claims
Eisai Inc.Lenvima$92$282,55412 claims
PfizerIbrance, Eliquis$686$272,38239 claims
AstraZenecaCalquence$3,359$254,15717 claims
Beigene USA, Inc.Brukinsa$83$181,70512 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$28$93,36633 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology & oncology providers in Wyomingon file to place this against a meaningful peer group, so we don't.

Other hematology & oncology in Casper

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →